Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ivermectin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: ivermectin. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-013276-46 Sponsor Protocol Number: N/A Start Date*: 2010-02-05
    Sponsor Name:Queen Victoria Hospital
    Full Title: The effect of oral Ivermectin on Demodex associated blepharitis
    Medical condition: Demodex Follicularum associated anterior blepharitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005015-40 Sponsor Protocol Number: IVER-303 Start Date*: 2021-04-29
    Sponsor Name:Chemo Research S.L.
    Full Title: A multicentre, phase III, double-blind, randomised, parallel, placebo-controlled trial to assess efficacy and safety of early administration of Ivermectin during 3 consecutive days to prevent SARS ...
    Medical condition: Coronavirus disease (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003255-15 Sponsor Protocol Number: Benzylbenzoat-Ivermectin-5020 Start Date*: 2020-12-17
    Sponsor Name:Landeskrankenhaus Salzburg
    Full Title: Investigation to assess the efficacy of benzyl benzoate 10/25% emulsion versus oral ivermectin for scabies treatment
    Medical condition: Scabies
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001994-66 Sponsor Protocol Number: ECIT-PRO19 Start Date*: 2020-05-06
    Sponsor Name:Fundació Assistencial Mútua Terrassa
    Full Title: Ramdomised clinical trial of ivermectin for treatment and prophylaxis of COVID-19
    Medical condition: SARS COVID-19
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001938-19 Sponsor Protocol Number: mdc-TTG-CT-002 Start Date*: 2022-03-10
    Sponsor Name:MedinCell S.A.
    Full Title: A multicentre randomised, Double-Blind, Placebo-controlled, Study to evaluate the efficAcy and safety of oral IVErmectin tablets in the prevention of COVID-19 (the SAIVE Trial)
    Medical condition: Prophylaxis of COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001971-33 Sponsor Protocol Number: CORIVER Start Date*: 2020-06-02
    Sponsor Name:Carmen Hidalgo
    Full Title: Pragmatic study "CORIVER": Ivermectin as antiviral treatment for patients infected by SARS-COV2 (COVID-19)
    Medical condition: SARS-COV2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002445-15 Sponsor Protocol Number: Prevent-COVID Start Date*: 2021-09-27
    Sponsor Name:InfectoPharm Arzneimittel und Consilium GmbH
    Full Title: Placebo-kontrollierte randomisierte doppel-blinde Phase III Studie zur Wirksamkeit und Sicherheit von Ivermectin Tabletten (Driponin®) für die Prophylaxe der COVID-19 Erkrankung bei im Haushalt leb...
    Medical condition: COVID-19 Post-Expositionsprophylaxe
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002091-12 Sponsor Protocol Number: HUVE-19-CT-001 Start Date*: 2020-05-15
    Sponsor Name:HUVEPHARMA EOOD
    Full Title: Multicenter, randomized, double-blind, placebo-controlled study investigating efficacy, safety and tolerability of ivermectin HUVE-19 in patients with proven SARS-CoV-2 infection (COVID-19) and man...
    Medical condition: confirmed SARS-CoV-2 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001474-29 Sponsor Protocol Number: SAINT Start Date*: 2020-05-07
    Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra
    Full Title: Pilot study to evaluate the potential of ivermectin to reduce COVID-19 transmission
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-004143-27 Sponsor Protocol Number: STRONG-FIX Start Date*: 2023-09-14
    Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)
    Full Title: Randomized non-inferiority clinical trial to evaluate the efficacy of a single fixed dose of 18 mg ivermectin for the treatment of uncomplicated strongyloidiasis
    Medical condition: Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointes...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10042254 Strongyloidiasis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002784-24 Sponsor Protocol Number: 2011-11 Start Date*: 2013-09-03
    Sponsor Name:Sacro Cuore - Don Calabria Hospital
    Full Title: STRONG TREAT 1 to 4 - randomized, open-label, multi centre, phase III clinical trial on multiple versus single dose of ivermectin for the treatment of strongyloidiasis
    Medical condition: strongyloidiasis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002723-16 Sponsor Protocol Number: PREMIVER Start Date*: 2018-04-20
    Sponsor Name:Universitaetsklinikum Tuebingen
    Full Title: Evaluation of the potential anti-malarial effect of ivermectin: a controlled human malaria infection trial
    Medical condition: In spite of remarkable progress over the last 15 years, malaria continues to be a major public health problem in the developing world with an estimated 214 million cases and 438.000 deaths in 2014....
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000157-40 Sponsor Protocol Number: RD.03.SPR.113322 Start Date*: 2017-06-15
    Sponsor Name:Galderma R&D SNC
    Full Title: Efficacy comparison of Ivermectin 1% topical cream associated with Doxycycline 40 mg Modified release (MR) capsules versus Ivermectin 1% topical cream associated with Placebo in the treatment of s...
    Medical condition: severe Rosacea
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000166-15 Sponsor Protocol Number: IVM-2021-01 Start Date*: 2021-03-03
    Sponsor Name:Meditop Gyógyszeripari Kft
    Full Title: A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ivermectin in asymptomatic and mild severity COVID-19 patients
    Medical condition: COVID 19 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002283-32 Sponsor Protocol Number: 2020-34 Start Date*: 2020-06-12
    Sponsor Name:OSPEDALE CLASSIFICATO EQUIPARATO SACRO CUORE DON CALABRIA - PRESIDIO OSPEDALIERO ACCREDITATO
    Full Title: Randomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the early Treatment of COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001999-20 Sponsor Protocol Number: RD.03.SPR.40027 Start Date*: 2006-10-10
    Sponsor Name:Galderma Research & Development SNC
    Full Title: ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (RO...
    Medical condition: Patients with papulo-pustular rosacea
    Disease: Version SOC Term Classification Code Term Level
    9.0 10039218 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002024-21 Sponsor Protocol Number: IVER-FNUSA-21 Start Date*: 2021-06-09
    Sponsor Name:Fakultní nemocnice u sv. Anny v Brně
    Full Title: Randomized placebo controlled clinical trial evaluating the safety and efficacy of ivermectin in hospitalized patients with Covid-19 disease
    Medical condition: Covid-19 disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000063-16 Sponsor Protocol Number: RD.03.SPR.109807 Start Date*: 2016-06-10
    Sponsor Name:Galderma R&D SNC
    Full Title: Efficacy and safety of CD5024 1% in acne vulgaris
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005423-37 Sponsor Protocol Number: GHRMRIPH1001 Start Date*: 2021-02-05
    Sponsor Name:Raincy Montfermeil intercommunal hospital group
    Full Title: Impact évaluation of an ivermectin single dose administration in the early phase of COVID-19 to negative viral load in SARS-CoV-2 determined by RT-PCR_ IVERCoV.
    Medical condition: patients with COVID 19 symptoms for less than 72 hours
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018319-13 Sponsor Protocol Number: RD.03.SPR.40106 Start Date*: 2010-08-17
    Sponsor Name:GALDERMA R&D SNC
    Full Title: A DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE ACTIVITY OF CD5024 1% CREAM IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA OVER 12 WEEKS TREATMENT
    Medical condition: PATIENTS WITH PAPULOPUSTULAR ROSACEA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039218 Rosacea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FI (Completed) SK (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Apr 23 23:26:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA